- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04336189
Optimal Chemopreventive Regimens to Prevent Malaria and Improve Birth Outcomes in Uganda
October 20, 2025 updated by: Grant Dorsey, M.D, Ph.D.
This trial tests the hypothesis that intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) + dihydroartemisin-piperaquine (DP) will significantly reduce the risk of adverse birth outcomes compared to IPTp with SP alone or DP alone.
This double-blinded randomized controlled phase III trial of 2757 HIV uninfected pregnant women enrolled at 12-20 weeks gestation will be randomized in equal proportions to one of three IPTp treatment arms: 1) SP given every 4 weeks, or 2) DP given every 4 weeks, or 3) SP+DP given every 4 weeks.
SP or DP placebos will be used to ensure adequate blinding is achieved in the study and follow-up will end 28 days after giving birth.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Malaria in pregnancy remains a major challenge in Africa, where approximately 50 million women are at risk for P. falciparum infection during pregnancy each year.
Among pregnant women living in malaria endemic areas symptomatic disease is uncommon, but infection with malaria parasites is associated with maternal anemia and adverse birth outcomes including abortions, stillbirth, preterm birth, low birth weight (LBW), and infant mortality.
The World Health Organization (WHO) recommends the use of long-lasting insecticidal nets (LLINs) and intermittent preventive treatment with sulfadoxine-pyrimethamine (IPTp-SP) for the prevention of malaria in pregnancy in endemic areas of Africa.
However, there is concern for diminishing efficacy of these interventions due to the spread of vector resistance to the pyrethroid insecticides used in LLINs and parasite resistance to SP.
Thus, there is an urgent need for new strategies for the prevention of malaria in pregnancy and improving birth outcomes.
Artemisinin-based combination therapies (ACTs) are now the standard treatment for malaria in Africa.
Dihydroartemisin-piperaquine (DP) is a fixed-dose ACT and an attractive alternative to SP for IPTp.
DP is highly efficacious, and the long half-life of piperaquine provides at least 4 weeks of post-treatment prophylaxis.
Recent randomized controlled trials showed that, compared to IPTp with SP, IPTp with DP dramatically reduced risks of malaria-specific outcomes but there were minimal differences between the SP and DP groups in risks of adverse birth outcomes.
The key question for this study is why IPTp with either SP or DP is associated with similar risks of adverse birth outcomes despite the far superior antimalarial activity of DP.
The likely explanation is that SP, a broad-spectrum antibiotic, protects against non-malarial causes of LBW and preterm birth.
The central hypothesis is that SP improves birth outcomes independent of its antimalarial activity and that IPTp with a combination of SP+DP will offer antimalarial and non-antimalarial benefits, thus providing superior prevention of adverse birth outcomes compared to either drug used alone.
To test this hypothesis, a double-blinded randomized clinical trial will conducted in a rural area of Uganda with very high malaria transmission intensity, where there is already an established infrastructure for clinical research.
Specific aims will be (1) to compare the risk of adverse birth outcomes among pregnant women randomized to receive monthly IPTp with SP vs. DP vs. SP+DP, (2) To compare safety and tolerability of IPTp regimens among pregnant women randomized to receive monthly IPTp with SP vs. DP vs. SP+DP, and (3) to compare risks of malaria-specific and non-malarial outcomes among pregnant women randomized to receive monthly IPTp with SP vs. DP vs. SP+DP.
This study will be the first to evaluate the efficacy and safety of a novel combination of well-studied drugs for improving birth outcomes and findings may well have important policy implications, with a change in standard practice for millions of pregnant women in Africa.
Study Type
Interventional
Enrollment (Actual)
2757
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Busia
-
Masafu, Busia, Uganda
- Infectious Diseases Research Collaboration Clinic - Masafu Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Viable singleton pregnancy confirmed by ultrasound
- Estimated gestational age between 12-20 weeks
- Confirmed to be HIV- uninfected by rapid test
- 16 years of age or older
- Residency within Busia District of Uganda
- Provision of informed consent
- Agreement to come to the study clinic for any febrile episode or other illness and avoid medications given outside the study protocol
- Willing to deliver in the hospital
Exclusion Criteria:
- History of serious adverse event to SP or DP
- Active medical problem requiring inpatient evaluation at the time of screening
- Intention of moving outside of Busia District Uganda
- Chronic medical condition requiring frequent medical attention
- Prior chemopreventive therapy or any other antimalarial therapy during this pregnancy
- Early or active labor (documented by cervical change with uterine contractions)
- Multiple pregnancies (i.e. twins/triplets)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: SP + DP placebo every 4 weeks
|
SP (Kamsidar) will be supplied by Kampala Pharmaceutical Industries (KPI), Uganda.
SP will be given as a single dose consisting of 3 full strength tablets.
Other Names:
|
|
Active Comparator: DP + SP placebo every 4 weeks
|
DP (Duo-Cotecxin) will be supplied by Holley-Cotec, Beijing, China.
DP will consist of 3 full strength tablets given once a day for 3 consecutive days.
Other Names:
|
|
Active Comparator: SP + DP given every 4 weeks
|
SP (Kamsidar) will be supplied by Kampala Pharmaceutical Industries (KPI), Uganda.
SP will be given as a single dose consisting of 3 full strength tablets.
Other Names:
DP (Duo-Cotecxin) will be supplied by Holley-Cotec, Beijing, China.
DP will consist of 3 full strength tablets given once a day for 3 consecutive days.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Risk of Having a Composite Adverse Birth Outcome
Time Frame: Time from first dose of study drugs up to 28 days postpartum, an average of 6 months
|
Composite adverse birth outcome defined as the occurrence of any of the following:
|
Time from first dose of study drugs up to 28 days postpartum, an average of 6 months
|
|
Incidence of Serious Adverse Events (SAE) Per Time at Risk
Time Frame: Time from first dose of study drugs up to 28 days postpartum, an average of 6 months
|
SAEs as defined by the July 2017 NIH DAIDS Toxicity Tables
|
Time from first dose of study drugs up to 28 days postpartum, an average of 6 months
|
|
Incidence of Any Grade 3 or 4 or Serious Adverse Events Per Time at Risk
Time Frame: Time from first dose of study drugs up to 28 days postpartum, an average of 6 months
|
Grade 3 and 4 AEs or SAEs as defined by the July 2017 NIH DAIDS Toxicity Tables
|
Time from first dose of study drugs up to 28 days postpartum, an average of 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants With Spontaneous Abortion
Time Frame: Time of delivery
|
Spontaneous abortion defined as fetal loss at < 28 weeks gestational age
|
Time of delivery
|
|
Incidence of Anemia Adverse Event Per Time at Risk
Time Frame: Day study drugs are first given until when study participants reach 28 days postpartum or early study termination, an average of 6 months
|
Grade 3-4 AEs as defined by the July 2017 NIH DAIDS Toxicity Tables
|
Day study drugs are first given until when study participants reach 28 days postpartum or early study termination, an average of 6 months
|
|
Incidence of Grade 3-4 AEs Possibly Related to Study Drugs
Time Frame: Day study drugs are first given until when study participants reach 28 days postpartum or early study termination, an average of 6 months
|
Grade 3-4 AEs possibly or definitely related to study drug defined by the July 2017 NIH DAIDS Toxicity Tables
|
Day study drugs are first given until when study participants reach 28 days postpartum or early study termination, an average of 6 months
|
|
Risk of Placental Malaria
Time Frame: At the time of delivery
|
Detection of malaria parasites or pigment by histopathology
|
At the time of delivery
|
|
Incidence of Malaria During Pregnancy
Time Frame: Day study drugs first given until delivery, an average of 6 months
|
Episodes of symptomatic malaria (incidence per person year at risk following initiation of study drugs)
|
Day study drugs first given until delivery, an average of 6 months
|
|
Microscopic Parasitemia During Pregnancy
Time Frame: Day study drugs first given until delivery, an average of 6 months
|
Proportion of routine samples with asexual parasites detected by microscopy
|
Day study drugs first given until delivery, an average of 6 months
|
|
Prevalence of Anemia During Pregnancy
Time Frame: Day study drugs are first given until delivery
|
Proportion of routine hemoglobin measurements < 11 g/dL
|
Day study drugs are first given until delivery
|
|
Stillbirth
Time Frame: Time of delivery
|
Stillbirth defined as infant born deceased at > 28 weeks gestational age
|
Time of delivery
|
|
Low Birth Rate
Time Frame: Time of delivery
|
Low birth weight defined as live birth with birth weight < 2500 gm
|
Time of delivery
|
|
Preterm Delivery
Time Frame: Time of delivery
|
Preterm delivery defined as live birth at < 37 weeks gestational age
|
Time of delivery
|
|
Small-for-gestational Age
Time Frame: Time of delivery
|
Small-for-gestational age defined as live birth with weight-for-gestational age < 10th percentile of reference population
|
Time of delivery
|
|
Neonatal Death
Time Frame: Time of delivery
|
Neonatal death defined as live birth with neonatal death within the first 28 days of life
|
Time of delivery
|
|
Microscopic or Sub-microscopic Parasitemia During Pregnancy
Time Frame: Day study drugs first given until delivery, an average of 6 months
|
Proportion of routine samples with asexual parasites detected by microscopy or qPCR
|
Day study drugs first given until delivery, an average of 6 months
|
|
Prevalence of Severe Anemia During Pregnancy
Time Frame: Day study drugs are first given until delivery, an average of 6 months
|
Proportion of routine hemoglobin measurements < 8 g/dL
|
Day study drugs are first given until delivery, an average of 6 months
|
|
Incidence of Stillbirth Adverse Event Per Time at Risk
Time Frame: Day study drugs are first given until when study participants reach 28 days postpartum or early study termination, an average of 6 months
|
Grade 3-4 AEs as defined by the July 2017 NIH DAIDS Toxicity Tables
|
Day study drugs are first given until when study participants reach 28 days postpartum or early study termination, an average of 6 months
|
|
Incidence of Congenital Anomaly Adverse Event Per Time at Risk
Time Frame: Day study drugs are first given until when study participants reach 28 days postpartum or early study termination, an average of 6 months
|
Grade 3-4 AEs as defined by the July 2017 NIH DAIDS Toxicity Tables
|
Day study drugs are first given until when study participants reach 28 days postpartum or early study termination, an average of 6 months
|
|
Incidence of Neutropenia Adverse Event Per Time at Risk
Time Frame: Day study drugs are first given until when study participants reach 28 days postpartum or early study termination, an average of 6 months
|
Grade 3-4 AEs as defined by the July 2017 NIH DAIDS Toxicity Tables
|
Day study drugs are first given until when study participants reach 28 days postpartum or early study termination, an average of 6 months
|
|
Incidence of Proteinuria Adverse Event Per Time at Risk
Time Frame: Day study drugs are first given until when study participants reach 28 days postpartum or early study termination, an average of 6 months
|
Grade 3-4 AEs as defined by the July 2017 NIH DAIDS Toxicity Tables
|
Day study drugs are first given until when study participants reach 28 days postpartum or early study termination, an average of 6 months
|
|
Incidence of Thrombocytopenia Adverse Event Per Time at Risk
Time Frame: Day study drugs are first given until when study participants reach 28 days postpartum or early study termination, an average of 6 months
|
Grade 3-4 AEs as defined by the July 2017 NIH DAIDS Toxicity Tables
|
Day study drugs are first given until when study participants reach 28 days postpartum or early study termination, an average of 6 months
|
|
Incidence of Postpartum Hemorrhage Adverse Event Per Time at Risk
Time Frame: Day study drugs are first given until when study participants reach 28 days postpartum or early study termination, an average of 6 months
|
Grade 3-4 AEs as defined by the July 2017 NIH DAIDS Toxicity Tables
|
Day study drugs are first given until when study participants reach 28 days postpartum or early study termination, an average of 6 months
|
|
Incidence of Pre-eclampsia Adverse Event Per Time at Risk
Time Frame: Day study drugs are first given until when study participants reach 28 days postpartum or early study termination, an average of 6 months
|
Grade 3-4 AEs as defined by the July 2017 NIH DAIDS Toxicity Tables
|
Day study drugs are first given until when study participants reach 28 days postpartum or early study termination, an average of 6 months
|
|
Incidence of Preterm Birth <28 Gestational Age Adverse Event Per Time at Risk
Time Frame: Day study drugs are first given until when study participants reach 28 days postpartum or early study termination, an average of 6 months
|
Grade 3-4 AEs as defined by the July 2017 NIH DAIDS Toxicity Tables
|
Day study drugs are first given until when study participants reach 28 days postpartum or early study termination, an average of 6 months
|
|
Incidence of Elevated Temperature Adverse Event Per Time at Risk
Time Frame: Day study drugs are first given until when study participants reach 28 days postpartum or early study termination, an average of 6 months
|
Grade 3-4 AEs as defined by the July 2017 NIH DAIDS Toxicity Tables
|
Day study drugs are first given until when study participants reach 28 days postpartum or early study termination, an average of 6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Grant Dorsey, MD, PhD, University of California, San Francisco
- Principal Investigator: Phil Rosenthal, MD, University of California, San Francisco
- Principal Investigator: Moses Kamya, MBChB, MMed, PhD, Makerere University; Infectious Diseases Research Collaboration
- Study Director: Abel Kakuru, MBChB, PhD, Infectious Diseases Research Collaboration
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 28, 2020
Primary Completion (Actual)
July 28, 2024
Study Completion (Actual)
July 28, 2024
Study Registration Dates
First Submitted
March 31, 2020
First Submitted That Met QC Criteria
April 2, 2020
First Posted (Actual)
April 7, 2020
Study Record Updates
Last Update Posted (Estimated)
November 6, 2025
Last Update Submitted That Met QC Criteria
October 20, 2025
Last Verified
June 1, 2025
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Vector Borne Diseases
- Urogenital Diseases
- Genital Diseases
- Mosquito-Borne Diseases
- Genital Diseases, Male
- Male Urogenital Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Infections
- Genital Diseases, Female
- Protozoan Infections
- Parasitic Diseases
- Malaria
- Reproductive Tract Infections
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antiprotozoal Agents
- Antiparasitic Agents
- Antimalarials
- Folic Acid Antagonists
- Anti-Infective Agents, Urinary
- fanasil, pyrimethamine drug combination
Other Study ID Numbers
- DPSP
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.